DFX Intelligence

Data Factory

Breyanzi

BREYANZI® (lisocabtagene maraleucel) is a CD19-directed, genetically modified, autologous T-cell immunotherapy for adult patients with certain types of lymphoma. See response rates and safety profile. Please see Important Safety Information including Boxed WARNINGS.

This is the graph view. The full profile, with its team, deals and sources, is on Venture Capital.Open the full profile →

Search this name across graphsid dfx:vc:0870e65c-abf1-4c24-81b7-dca417baaa43

Data as of Sep 17, 2026 (this record's last observation) from Sworn filings; Announcements; Limited partners. Page built Sep 19, 2026, 10:51 AM UTC and rebuilt at most every 15 minutes.

Relationships: 1
Dated events: 0
On other graphs: 1
Observed: Sep 16, 2026 to Sep 17, 2026
4 observations

Across DFX

same identity by shared identifier, citation, or a bridge measured by hand

Private Equityidentity

Breyanzi

Portfolio company · cited

Facts

fact = as filed or announced; derived = computed by DFX; estimate = a band, never a point

Rounds: 0
Investors: 1
People: 0
Website: breyanzihcp.com

Investors

Investor	Class	Fund	Partner	Role	Attribution
Omega Fund Management, LLC	Institutional VC	n/a	n/a	unknown	Unknown

Relationships

Invested in (1)

← Omega Fund Management, LLCFirmPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site

Dated events

No dated event names this entity yet.

Provenance

Graph: Venture Capital
Canonical id: dfx:vc:0870e65c-abf1-4c24-81b7-dca417baaa43
First observed: Sep 16, 2026
Last observed: Sep 17, 2026 2 days ago
Resolution: Identity across graphs by shared identifier (CRD, CIK, EIN, ADV fund id, individual CRD) or citation; a name match is shown as a candidate and never merged.